Santarus, Inc. (NASDAQ:SNTS)

CAPS Rating: 2 out of 5

A pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians.

Recs

0
Player Avatar Brian7992 (< 20) Submitted: 8/11/2009 2:29:09 PM : Outperform Start Price: $3.12 SNTS Score: +59.17

Buy me now!

Featured Broker Partners


Advertisement